2024

Cancer

Valar Labs has secured a $22 million investment to advance its AI platform to predict cancer treatment outcomes. The biotech company aims to use this funding to expand its focus to more tumors and treatment options, enhancing the predictability and efficiency of cancer care. 
Moreover, Valar Labs has developed Vesta, an AI tool targeting bladder cancer. This platform leverages visual AI to analyze histological images, identifying key therapy response indicators. By working with international medical institutes, Valar evaluated over a thousand patients, using this data to refine Vesta’s predictive capabilities. 
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter">
 <div class="wp-block-embed__wrapper"> 
 <blockquote class="twitter-tweet" data-width="550" data-dnt="true">
 This financing will advance Vesta, the world's first AI test to predict treatment response in bladder cancer and catalyze expansion into new cancer types.— Valar Labs (@valarlabs) <a href="https://twitter.com/valarlabs/status/1796216295605653749?ref_src=twsrc%5Etfw" target="_blank" rel="noopener">May 30, 2024</a>
 </blockquote> 
 </div>
</figure> 
The AI-driven platform assists pathologists in making accurate diagnoses without replacing their expertise. This aims to eliminate the prolonged and often uncertain nature of traditional treatments like BCG therapy, which only succeeds about half the time.&nbsp; 
Valar’s technology provides interpretable and actionable data to doctors, facilitating better clinical decision-making. 
Expanding AI in Oncology&nbsp; 
Valar Labs plans to extend its AI capabilities to a wider range of cancers with the new funding. The company’s models, trained on extensive datasets, aim to reduce the time and cost associated with ineffective therapies.&nbsp; 
Valar’s commitment to enhancing clinical decision-making is supported by notable investors such as <a href="https://www.dcvc.com/" target="_blank" rel="noreferrer noopener nofollow">DCVC</a> and Andreessen Horowitz. The $22 million Series A funding will drive the commercialization of Vesta and the development of new AI applications in oncology.&nbsp; 
Valar Labs’ AI platform, Vesta, represents an advancement in personalized cancer treatment. With substantial financial support, the company is poised to expand its innovative approach to various cancer types, aiming to improve patient outcomes and integrate more effectively into the healthcare system. 
<blockquote class="wp-block-quote is-layout-flow wp-block-quote-is-layout-flow"> 
 Also Read: <a href="https://www.cryptotimes.io/2024/05/31/openai-stops-ai-powered-deceptive-influence-in-5-campaigns/" target="_blank" rel="noreferrer noopener">OpenAI Stops AI-Powered Deceptive Influence in 5 Campaigns</a> 
</blockquote>

Valar Labs Raises $22M for AI-Driven Cancer Treatment Predictions

The Crypto Times

Other articles published on May 31, 2024

Terraform Labs, Do Kwon reach preliminary deal with SEC in TerraUSD case

Investors Increase Interest in Terra (LUNA) After Settlement

Ethereum Bloodbath: Over $55 Million In Longs Liquidated As Price Plummets

U.S. Treasury Identifies Financial Risks in Emerging NFT Market

Mt Gox not dumping Bitcoin just yet, Hong Kong boots out crypto exchanges: Asia Express

'Dogecoin Killer' Shiba Inu's Burn Rate Spikes Nearly 250% As Whales Show Interest In The Memecoin

Join our free newsletter for daily crypto updates!